Iovance Biotherapeutics, Inc. IOVA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s financing cash flow?
- Iovance Biotherapeutics, Inc. (IOVA) reported financing cash flow of $94.34M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s financing cash flow changed year-over-year?
- Iovance Biotherapeutics, Inc.'s financing cash flow decreased by 34.2% year-over-year, from $143.32M to $94.34M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s financing cash flow has grown at a 5.9% compound annual growth rate (CAGR), from $239.27M to $300.77M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.